FOR IMMEDIATE RELEASE
Monday, Nov 21, 2005
Neurome, Inc. Announces Broadened Collaboration with Wyeth
Companies to Determine Efficacy of Drug Candidates in Reversing Pathology
in Brain Regions Known to be Associated with Neurodegenerative Disease
LA JOLLA, CALIFORNIA, November 21, 2005 – Neurome today announced the expansion of its discovery research collaboration with Wyeth (NYSE:WYE), which is currently focused on the investigation of certain aspects of CNS disease using Neurome’s proprietary discovery technologies and expertise in quantitative neuropathology. Under the terms of the expanded research collaboration, Neurome will evaluate the effectiveness of possible drug candidates as part of intervention studies in an animal model of neurodegenerative disease. Financial terms of the agreement were not disclosed.
“Our partnership with Wyeth has been highly productive,” commented Floyd E. Bloom, M.D., Chief Executive Officer, Chief Scientific Officer and Chairman of the Board of Neurome. “We look forward to increasing our efforts with Wyeth to include the evaluation of potential therapeutic compounds to determine their effectiveness against neurodegenerative illnesses.”
“The technology we have developed at Neurome is ideally suited to the comprehensive evaluation of drug candidates in preclinical animal models of disease,” said Warren G. Young, Ph.D., President and Chief Operating Officer of Neurome. “We are delighted that Wyeth has decided to expand the scope of its work with us to include these studies, which we believe will provide highly relevant data, useful in determining successful reversal of disease pathology.”
Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) – usually fatal neurodegenerative disorders that are currently untreatable and share characteristics which make them particularly amenable to Neurome's expertise and technologies. Neurome is also engaged in the research and development of novel delivery systems for targeted mucosal vaccines.
Since its founding in 2000, Neurome has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. Neurome’s unique technologies to measure and assess neurodegenerative processes at work – at the molecular, cellular and macroscopic levels – are ideally suited to identify the earliest evidence of pathology in models of human diseases of the Central Nervous System, as well as to evaluate the comparative effectiveness of pharmaceutical candidates for intervention. The company dedicates these technologies to discovery and development of drugs to provide effective treatments for diseases characterized by neurodegeneration. Detailed information on the Neurome technologies and the scientific and medical challenges of human neurodegenerative disorders are available at Neurome’s website: www.neurome.com.